Qure.ai launches FDA-cleared AI solution for advanced lung nodule quantification on CT scans

The new AI solution is now available to support radiologists and pulmonologists in analysing lung nodules

Qure.ai, a global innovator in medical imaging AI, announced a pivotal 510(k) FDA clearance for its AI-powered chest CT solution – qCT LN Quant. The new AI solution is now available to support radiologists and pulmonologists in analysing lung nodules on non-contrast chest CT scans and tracking volumetric growth as part of progression monitoring.

qCT LN Quant joins the Qure.ai US AI-powered Lung Cancer care continuum, featuring end-to-end AI solutions to identify, measure, manage, and monitor lung health. These help to support clinicians at healthcare institutions and drive early detection. This includes ‘qXR LN’ for the early detection and localization of lung nodules on chest X-rays to support early lung cancer detection beyond traditional CT-based screening initiatives, and ‘qTrack,’ a multi-modality lung nodule management platform that integrates with Electronic Medical Records (EMRs) to help find, report, collaborate, and prioritize lung cancer patient cases.

“We are delighted to showcase qCT LN Quant at the American Association for Bronchology and Interventional Pulmonology (AABIP) conference in North Carolina,” states Bhargava Reddy, Chief Business Officer, Oncology at Qure.ai. “Now, we have the next stage solution in the AI-optimised patient pathway, to evaluate lung nodules on at-risk patient CT scans, giving precise quantitative characterization, plus tracking volumetric growth over time.”